Diopsys, Inc. Announces Settlement with the Department of Justice
MIDDLETOWN, Pa.--(BUSINESS WIRE)-- Diopsys, Inc. has settled all claims with the Department of Justice related to its Nova ERG device marketing activities from the period of 2015-2021. The settlement provides for a series of guaranteed payments totaling $1,225,000 and contingent payments up to a maximum of $13,025,000 to be made over a period of 6 years.
“We take regulatory requirements seriously and this agreement reinforces that commitment,” stated Michael Egleston, CFO, Diopsys, Inc. “With the settlement now complete, Diopsys can proceed with submitting a new 510K application to the FDA for its redesigned ERG device and working to restore its ERG presence in the US marketplace.”
About Diopsys, Inc.
Diopsys, Inc. is a medical device company commercializing the NOVA™ Vision Testing System. NOVA is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the USA and select countries outside of the USA. ERG is only available outside of the USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250328460541/en/
Michael Egleston
[email protected]
Source: Diopsys, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on China’s Non-Life Insurance Segment
- Eylsia Nicolas Unveils EDTV Prototype Amid National AI‑Education Debate as Her Music Surges Past 750 Million Views and Holds Multiple Global Top‑Ten Chart Positions
- AM Best Upgrades Issuer Credit Rating of Singapore Reinsurance Corporation Limited
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share